Vistagen Therapeutics Reports Q1 FY2027 Financial Results

What Happened

• On August 14, 2026, Vistagen Therapeutics, Inc. announced its financial results for the fiscal 2027 first quarter ended June 30, 2026 via a press release. The press release was furnished to the SEC as Exhibit 99.1 to the Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition). The filing includes a standard disclaimer that the information is furnished, not “filed,” under the Securities Exchange Act.

Key Details

• Date announced: August 14, 2026.
• Reporting period: Fiscal Q1 2027, quarter ended June 30, 2026.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Signature: Report signed by Shawn K. Singh, President and CEO of Vistagen Therapeutics.

Why It Matters

• This 8-K signals that Vistagen has publicly released its quarterly earnings and related financial information; retail investors should read the furnished press release (Exhibit 99.1) for specifics on revenue, expenses, net income/loss, cash position and any commentary on operations or outlook.
• The filing’s “furnished, not filed” status is a legal detail that limits certain liabilities under Section 18 of the Exchange Act but does not change the need for investors to review the disclosed quarterly results and other SEC filings for investment decisions.